

Table 7.7
Cancer of the Corpus and Uterus, NOS (Invasive)

Survival Rates, by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival Rates									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	73	-	-	31	-	-
1970-1973 ^a	-	-	-	81	-	-	44	-	-
1975-1977 ^b	87.6	92.7	87.0	88.7	93.3	88.2	61.0	84.4 ^f	56.1
1978-1980 ^b	83.6	91.7	82.5	84.9	93.1	83.8	55.9	82.0 ^f	50.5
1981-1983 ^b	81.9	91.3	80.6	83.3	92.3	82.2	52.5	82.8 ^f	47.2
1984-1986 ^b	83.5	93.6	82.1	85.0	93.9	83.8	57.8	83.6 ^f	54.0
1987-1989 ^b	83.4	90.2	82.3	85.0	91.0	84.1	58.3	84.6 ^f	54.1
1990-1992 ^b	84.6	90.0	83.7	86.7	92.2	85.8	54.9	72.5 ^f	50.9
1993-1995 ^b	84.0	90.1	82.9	85.7	91.6	84.7	60.1	81.8	55.3
1996-1998 ^b	84.5	90.1	83.5	86.2	91.1	85.3	62.4	82.4	57.7
1999-2005 ^b	84.4 ^e	89.2 ^e	83.4 ^e	86.5 ^e	90.8	85.7 ^e	61.5	74.5	57.9
5-Year Period Survival Rates^{cd}									
Year of Diagnosis:									
1999-2005	82.9	89.0	81.5	84.6	89.8	83.7	61.5	79.3	57.5
Stage Distribution (%) 1999-2005^c									
All Stages									
Number of cases	51,071	8,270	42,801	43,156	6,409	36,747	3,948	658	3,290
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	69	73	68	70	74	70	53	64	51
Regional	19	17	19	18	17	19	24	16	26
Distant	8	6	8	7	6	8	16	13	16
Unstaged	4	4	4	4	4	4	7	7	7
5-Year Relative Survival Rates, 1999-2005^c									
Age at Diagnosis:									
Ages <45	89.5	-	-	90.3	-	-	81.6	-	-
Ages 45-54	88.2	-	-	89.2	-	-	70.8	-	-
Ages 55-64	85.5	-	-	87.7	-	-	62.2	-	-
Ages 65-74	79.9	-	-	83.0	-	-	51.5	-	-
Ages 75+	72.2	-	-	74.1	-	-	48.2	-	-
Ages <65	87.1	-	-	88.6	-	-	68.7	-	-
Ages 65+	76.7	-	-	79.3	-	-	50.5	-	-
Stage:									
All Stages	82.9	89.1	81.6	84.7	89.7	83.7	61.3	78.7	57.4
Localized	95.7	96.4	95.6	96.4	96.5	96.5	84.9	92.3	82.7
Regional	67.4	80.8	64.8	69.6	81.9	67.3	46.1	67.5 ^f	42.9
Distant	17.4	29.8	15.3	18.8	31.8	16.7	10.5	21.5 ^f	8.4
Unstaged	56.1	84.9	49.3	56.2	83.4	50.5	38.2	81.2 ^f	26.9

^a Rates are based on End Results data from a series of hospital registries and one population-based registry.

^b Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2006.

^c Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2005.

^d The remaining 13 SEER Areas contribute cases for the entire period 1999-2005. Rates are based on follow-up of patients into 2006. Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2003-2005: 0-1 year survival),

(2002-2004: 1-2 year survival), (2001-2003: 2-3 year survival), (2000-2002: 3-4 year survival), (1999-2001: 4-5 years survival).

^e The difference in rates between 1975-1977 and 1999-2005 is statistically significant ($p < .05$).

^f The standard error of the survival rate is between 5 and 10 percentage points.

^g The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.